CSL Limited
(ASX:CSL) says the European Commission has approved IDELVION for the treatment of patients with haemophilia B.
The drug can be used for all age groups and was recently approved in the United States and Canada.
Idelvion will be launched in European markets in the coming months, as market access and pricing are obtained.
Haemophilia B affects more than 10,000 people throughout Europe.
CSL reported a net profit of $983.85 million at 31 December 2015.
